ENTX

In the past six months, Entera Bio Ltd. experienced several significant stock events: In June 2026, the FDA provided positive feedback on a streamlined registrational Phase 3 study for EB613, with the company planning to initiate Phase 3 in late 2026. In July 2026, Entera Bio completed an oversubscribed $275 million private placement, led by existing investor BVF Partners, to fund the upcoming Phase 3 trial. In September 2026, Cantor Fitzgerald initiated coverage with an "Overweight" rating and a $12.58 price target, following Leerink Partners' "Outperform" rating and $9 price target. The company released its Q1 2026 earnings on May 8, 2026, and Q2 2026 earnings on August 7, 2026. As of September 21, 2026, Entera Bio's stock was trading at $2.96, marking a 52.6% increase year-to-date from its $1.94 price at the beginning of 2026.